Navigation Links
SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
Date:11/7/2007

romising therapeutic option for patients with unstable angina and non-ST elevation MI undergoing PCI ," said Rick Veltri, M.D., Group Vice President of Global Clinical Research, Cardiovascular and Metabolic Disease, Schering- Plough Research Institute. "With our global Phase III clinical development program underway, we are continuing to evaluate the potential for TRA as a novel agent in reducing the incidence of cardiovascular events with no incremental bleeding when added to standard of care in the treatment of patients with acute coronary syndromes or established vascular disease," added Veltri.

The results were presented today at the American Heart Association Scientific Sessions in Orlando, FL, in a session titled "Thrombin Receptor Antagonist Is a Selective, Potent Inhibitor of PAR-1 Activity With Predictable Pharmacokinetics."

About TRA-PCI

The Phase II TRA-PCI Trial was a multinational, randomized, double-blind, placebo-controlled dose-ranging trial assessing oral loading doses and maintenance doses of TRA. The trial enrolled 1,030 patients randomized to one of three oral loading doses of TRA (10 mg, 20 mg, 40 mg) plus standard of care (clopidogrel + aspirin) or placebo plus standard of care in a 3:1 ratio of active drug to placebo. Patients who received a TRA-loading dose and subsequently underwent PCI (n=573) were randomized to one of three oral daily maintenance doses of TRA (0.5 mg, 1.0 mg, 2.5 mg). Patients who received placebo were randomized to receive standard of care alone. The total duration of treatment was 60 days. Patients were followed for an additional 60 days post-treatment.

A secondary endpoint in a sub-study within the primary evaluable patient cohort was inhibition of platelet aggregation (IPA) induced by appropriate agonists relative to baseline.

TRA-PCI results were first presented at a late-breaking clinical trial session at the March 2007 Scientific Sessions of the American College of Cardiology/i2 Summit
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), a ... and inoperable solid tumor cancers, announced today that CEO ... Annual Phacilitate Immunotherapy Forum in Washington D.C. ... place on January 26 at 10:30 a.m. EST at the ...
(Date:1/23/2015)... all-time hits leader, is the new spokesperson for the topical ... announced. "Pete,s a Hall of Famer in our ... with Myoflex," said Ducere Pharma Chief Executive Officer Chris ... across all generations. The passion and intensity that Pete brought ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Pete Rose bets on Myoflex to relieve aches and pains 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... Cetero Research , the leading early-stage contract ... "Jay" Dixon to Senior Vice President, Quality and Compliance. ... pharmaceutical, biotechnology and CRO industries, and will bring his ... market leadership position. (Photo:   http://photos.prnewswire.com/prnh/20110426/PH89541 ...
... Protect Pharmaceutical Corporation (OTCBB: PRTT) today announced its Board ... Sesha as its Chief Executive Officer and Chairman of ... the Chief Operating Officer and Board Member in March ... where he was the Founder and CEO. ...
Cached Medicine Technology:Cetero Research Names 25-Year Industry Veteran James Dixon to Head Quality and Compliance 2Protect Pharmaceutical Corporation Appoints Chief Executive Officer and Chief Financial Officer 2
(Date:1/22/2015)... with its top dressmaking technologies, has been a leading dress ... its latest designs of wedding dresses and launching a site-wide ... all the fresh new products are designed for 2015, and ... off. All the clothes from LunaDress follow up with the ...
(Date:1/22/2015)... 22, 2015 Padre Murphy's and Owner Tom ... Pro Player Health Alliance (PPHA). The PPHA's passion ... getting everyone, including NFL greats, treated for obstructive sleep apnea ... groups supporting the cause in the valley. The most recent ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
(Date:1/22/2015)... A new white paper by The Beryl Institute ... long-term care environment as well as provides recommendations for ... “The Power of Person-Centeredness in Long-Term Care: A View ... patient, resident and family experience in long-term care and ...
(Date:1/22/2015)... released a new blog post presenting the basic features of ... an accidental death and dismemberment rider for a car insurance ... benefits if the insured dies in an accident. Accidental death ... insurance. , AD&D is not expensive and can be ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... to revolutionize senior home care industry!PALO ALTO, Calif., ... Alto, California released its new caregiver training program ... exclusive to Home Care Assistance 1-866-4-LiveIn(TM), promotes longevity ... an emphasis on lifestyle, healthy diet, physical activity, ...
... Kidz-Med ThermofocusWESTON, Fla., May 22 Kidz-Med, Inc., a ... is excited to see that awareness for a new ... taking a child,s temperature with the Kidz-Med Thermofocus 5-in-1 ... The Doctors , renowned pediatrician Dr. Jim Sears, ...
... 22 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. ("Bioniche"; ... today provided an update on its Phase III ... bladder cancer. On March 31st, the Company announced ... Phase III registration trial evaluating Urocidin in the ...
... protein linked to tumor growth for clues to better treatments ... have found that levels of the protein caveolin-1 found in ... predict a patient,s prognosis and may provide a pathway to ... a role in how cells absorb things, in the stromal ...
... is what leads to well-being , , FRIDAY, May 22 (HealthDay ... may sound like a sure ticket to happiness, but a ... Rochester in New York tracked 147 college graduates, evaluating their ... one year after graduation, and then 12 months later. , ...
... to manufacturers by month,s end , , FRIDAY, May 22 (HealthDay ... a bit nearer Friday, with government health officials saying they ... shot. , "Today CDC received, from one institution, a candidate ... Science and Public Health Program said during a Friday news ...
Cached Medicine News:Health News:Home Care Assistance's Exclusive Balanced Care Method(TM) Designed to Promote Longer, Healthier Lives 2Health News:Home Care Assistance's Exclusive Balanced Care Method(TM) Designed to Promote Longer, Healthier Lives 3Health News:Awareness Increases on New Health and Safety Technology for Kids 2Health News:Awareness Increases on New Health and Safety Technology for Kids 3Health News:Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well 2Health News:Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well 3Health News:Looks, Money, Fame Don't Bring Happiness 2Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 2Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 3Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 4Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 5Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 6Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 7Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 8Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 9Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 10Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 11Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 12Health News:CDC Has Candidate Viruses for Swine Flu Vaccine 13
Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique. Round knurled handle. Manufactured in titanium....
#2 10 mm hook. Flat serrated handle with polished finish. Overall length: 5.5 inches....
7 mm flattened hook. Flat serrated handle with polished finish. Overall length: 4.9 inches....
Left angled 5 mm blunt hook. Overall length: 9.9 inches....
Medicine Products: